Wilson Therapeutics AB (Publ) Year-End Report 2017
“After a highly successful year, we are excited that we now have entered the pivotal phase of development for WTX101. Backed by positive Phase 2 data, an experienced international team and a solid balance sheet, we are very well positioned to advance WTX101 through Phase 3.” – Jonas Hansson, CEO.OCTOBER 1 – DECEMBER 31, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 52.8 M (loss: 34.1) · Loss per share, before and after dilution, totaled SEK 2.00 (loss: 1.33) · At December 31, cash and cash equivalents amounted to SEK 468.7 M (386.6) JANUARY